<DOC>
	<DOCNO>NCT00544232</DOCNO>
	<brief_summary>The present clinical trial investigate efficacy sequential interval-shortened dose-intensified preoperative use epirubicin , paclitaxel CMF preoperative sequential administration epirubicin cyclophosphamide follow paclitaxel breast cancer . In addition , influence darbepoetin alfa response rate quality life investigate treatment arm .</brief_summary>
	<brief_title>Preoperative Epirubicin Paclitaxel Aranesp Study ( PREPARE )</brief_title>
	<detailed_description>Arm A : Sequential treatment standard dose Epirubicin ( 90 mg/m2 ) /cyclophosphamide ( 600 mg/m2 ) d1 , q21d - 4× follow paclitaxel ( 175 mg/m2 ) d1 , q21d - 4× . Pegfilgratim use secondary preventive febrile neutropenia standard arm study , exceptional case also severe febrile neutropenia necessitate postponement treatment one week ± Darbepoetin alfa 1 × 4.5 µg/kg body weight every two week start first epirubicin dose ( day 1 ) 14 day last dose paclitaxel Daily oral intake 200 mg iron unless complication occur take iron Arm B : sequential dose-intensified , interval-shortened treatment Epirubicin ( 150 mg/m2 ) d1 , q14d - 3× follow paclitaxel ( 225 mg/m2 ) d1 , q14d - 3× , follow CMF ( 600/40/600 mg/m2 ) d1/d8 , q28d - 3× Obligatory pegfilgratim 6 mg epirubicin and/or paclitaxel : subcutaneous injection day 2 . After CMF pegfilgrastim use secondary preventive measure ± Darbepoetin alfa 1 × 4.5 µg/kg body weight every two week start first dose epirubicin ( day 1 ) 14 day last dose CMF Daily oral dose 200 mg iron unless complication occur take iron . Primary goal : Determining relapse-free survival time overall survival dose-intensified sequential preoperative chemotherapy include anthracycline taxan and/or preoperative chemotherapy include anthracycline follow taxan standard dose</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Histologically confirm breast cancer : least three fast biopsy . Primary tumor ≥2 cm acc . clinical measurement manifestation inflammatory breast cancer . No systemic metastasis , exclusion chest xray , sonogram upper abdomen skeletal scintiscan . Age ≥18 year ≤65 year . ECOG &lt; 2/WHO 01 Adequate organ function define SGOT bilirubin ≤ 1.5× upper limit WBC ≥ 3000 /µL Neutrophils ≥ 1000 /µL Platelets ≥ 100,000 /µL Serum creatinine &lt; 2.0 mg/dL Unremarkable heart echo No florid hepatitis Written consent participate treatment optimization protocol Multicentricity various quadrant ( contact study office ) Known allergy E. coliproduced medication Known allergy medication contain cremophor ( e.g. , cyclosporin A ) Patients receive immunosuppressant therapy Lack consent inform patient Lack willingness keep disclose personal medical data part study Pregnancy , nurse Secondary malignancy , exclude basalioma skin carcinoma situ cervix receive curative therapy Preexisting treatmentresistant cardiac disease , coronary heart disease , arrhythmia , cardiac insufficiency Patients uncontrolled hypertension ( diastolic &gt; 95 mmHg ) A history convulsion Known hypersensitivity darbepoetin alfa ingredient know hypersensitivity rHuEPO</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>neoadjuvant therapy</keyword>
	<keyword>pCR rate</keyword>
</DOC>